Hemab Therapeutics Holdings, Inc. (COAG) stock
Close on Nov 11, 2026Market cap $1.84BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $1.84B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.28
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Book value per share
- $9.19
- Diluted shares
- 47M
Trading
- Previous close
- $38.77
- Open
- $38.77
- Day's range
- $36.07 – $40.92
- Volume
- 655,782
- Average volume (20 days)
- 514,920
- RSI (14 days)
- 50.8
- Volatility (1 year)
- 88.7%
- Relative volume
- 1.43×
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | COAG | S&P 500 | Difference | COAG per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +24.4% | -2.4% | +26.8 pts | ||
| 3 months | -24.0% | -1.2% | −22.8 pts |
Press releases
Releases Hemab Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
Hemab Therapeutics stock: common questions
What is Hemab Therapeutics's stock price?
COAG closed at $39.33 on Nov 11, 2026, up 1.44% on the day.
What is Hemab Therapeutics's market cap?
Hemab Therapeutics was worth $1.84B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
Does Hemab Therapeutics pay a dividend?
No. Hemab Therapeutics has not paid a cash dividend over the last twelve months.
How many COAG shares are sold short?
3M shares were sold short at the latest FINRA report, 8.79% of the float, or 7.3 days of average trading volume.
Who are Hemab Therapeutics's competitors?
Companies most similar to Hemab Therapeutics by business, industry and size include AMGN, GILD, MRNA, BIIB, BNTX.
See a number that looks wrong?